Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared]

K M Kostner1, G M Kostner

  • 1Abteilung für Kardiologie, Innere Medizin II, Universität Wien. kkostner@mail.kard.akh-wien.ac.at

Wiener Klinische Wochenschrift
|November 17, 1998
PubMed
Summary

Statins effectively reduce coronary heart disease mortality by up to 30% and lower LDL-cholesterol by over 50%. Cost-effectiveness is highest in high-risk patients, with six statins offering varied pharmacological profiles.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Der Internist·2014
Same author

Fluorescence labeling and interaction of atherogenic lipoproteins with cultured cells.

Journal of fluorescence·2013
Same author

Transfer of pyrene-dietherphosphatidylcholine to serum lipoproteins.

Journal of fluorescence·2013
Same author

Expression of fat mobilizing genes in human epicardial adipose tissue.

Atherosclerosis·2011
Same author

Therapy of hyper-Lp(a).

Handbook of experimental pharmacology·2006
Same author

Does lipoprotein(a) predict risk in type 2 diabetes?

European journal of clinical investigation·2006

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Clinical Therapeutics

Context:

  • Large-scale trials demonstrate statins reduce coronary heart disease (CHD) mortality by up to 30%.
  • Pharmacological LDL-cholesterol reduction exceeding 50% is now achievable, previously only by LDL-apheresis.
  • Cost-effectiveness of lipid-lowering therapy varies significantly with patient coronary risk.

Purpose:

  • To analyze the pharmacological and clinical differences among the six available statins.
  • To highlight the varying capacities of statins in reducing LDL-cholesterol, triglycerides, and potential drug interactions.
  • To discuss the optimal application of statins based on patient risk and cost-effectiveness.

Summary:

  • Statins are effective lipid-reducing therapies that significantly decrease CHD mortality.

Related Experiment Videos

  • Current statins achieve substantial LDL-cholesterol reduction, primarily via LDL-receptor induction in the liver.
  • Pharmacological differences exist among statins, influencing their efficacy in triglyceride reduction and drug interactions.

    • Impact:

    • Provides a comprehensive overview of statin pharmacology and clinical actions for healthcare professionals.
    • Informs treatment decisions by detailing cost-effectiveness based on patient coronary risk.
    • Contributes to optimizing lipid-lowering strategies for cardiovascular disease prevention.